6700 Park Avenue, Suite 200
Montreal, Quebec
Canada H2V 4H9
Phone: 514-270-3991

John Hooper, president and CEO
Privately Held


Founded in March 1999, Galileo Genomics Inc. is a population genomics company focused on the discovery of disease-susceptibility genes in common human diseases, through the application of genetics to founder populations.

Galileo’s research relies on the study of genetic data collected from the Quebec Founder Population, a population of 6 million distantly related individuals descended from a small group of roughly 2,500 common ancestors who arrived from France between 1608 and 1760.

Galileo has several in-house research projects for the discovery of genes in human genetic diseases, including psychiatric, neurological, cardiovascular, metabolic, dermatological, respiratory, gastrointestinal and bone disorders, that can be used as targets for drug development programs and diagnostic applications. It also is pursuing research programs to develop innovative technologies for ultra-high-throughput DNA genotyping and proteomics.

Galileo is building a Biobank of DNA and other tissue samples to discover genes for its own account, form alliances with pharmaceutical and biotechnology business partners and provide candidate gene validation services to these companies.


Strategic alliance for coronary heart disease, obesity and depression: Myriad Genetics Inc.